MEBIAS
Mining the full potential of GPCR signaling to innovate novel drugs
Mebias
Protein-NMR Conformation Driven Drug Discovery
Our proprietary membrane protein-NMR drug discovery platform identifies molecules that bind to G-protein coupled receptor (GPCR) targets, eliminating on-target adverse effects that limit therapeutic index.
We know the value of innovative drug discovery and development…
MEBIAS’ business model is comprised of advancing and partnering Mebias’ wholly owned molecules into early clinical development. The company has identified an Investigational New Drug targeting the mu-opioid receptor in Phase 1 Clinical Studies. We are also developing Sphingosine 1-phosphate receptor agonists with the aim of treating neuropathic pain and neuroinflammation.
MEB-1170 is in Phase 1 human clinical trials
Address
101 College Street, Suite 210
New Haven, CT 06510
EMAIL US
info@mebiasdiscovery.com